- Home
- HOOK vs CNFR Comparison
HOOK vs CNFR Comparison
Compare HOOK & CNFR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HOOK
- CNFR
- Stock Information
- Founded
- HOOK 2011
- CNFR 2009
- Country
- HOOK United States
- CNFR United States
- Employees
- HOOK N/A
- CNFR N/A
- Industry
- HOOK Biotechnology: Pharmaceutical Preparations
- CNFR Property-Casualty Insurers
- Sector
- HOOK Health Care
- CNFR Finance
- Exchange
- HOOK Nasdaq
- CNFR Nasdaq
- Market Cap
- HOOK 9.3M
- CNFR 9.5M
- IPO Year
- HOOK 2019
- CNFR 2015
- Fundamental
- Price
- HOOK $1.25
- CNFR $0.74
- Analyst Decision
- HOOK Buy
- CNFR
- Analyst Count
- HOOK 4
- CNFR 0
- Target Price
- HOOK $10.67
- CNFR N/A
- AVG Volume (30 Days)
- HOOK 62.9K
- CNFR 5.2K
- Earning Date
- HOOK 08-07-2025
- CNFR 08-12-2025
- Dividend Yield
- HOOK N/A
- CNFR N/A
- EPS Growth
- HOOK N/A
- CNFR N/A
- EPS
- HOOK N/A
- CNFR 1.96
- Revenue
- HOOK $9,351,000.00
- CNFR $64,021,000.00
- Revenue This Year
- HOOK N/A
- CNFR $25.91
- Revenue Next Year
- HOOK N/A
- CNFR N/A
- P/E Ratio
- HOOK N/A
- CNFR $0.38
- Revenue Growth
- HOOK N/A
- CNFR N/A
- 52 Week Low
- HOOK $0.72
- CNFR $0.42
- 52 Week High
- HOOK $6.77
- CNFR $1.91
- Technical
- Relative Strength Index (RSI)
- HOOK 38.94
- CNFR 42.17
- Support Level
- HOOK $1.23
- CNFR $0.76
- Resistance Level
- HOOK $1.30
- CNFR $0.81
- Average True Range (ATR)
- HOOK 0.06
- CNFR 0.02
- MACD
- HOOK -0.03
- CNFR -0.01
- Stochastic Oscillator
- HOOK 5.97
- CNFR 1.14
About HOOK HOOKIPA Pharma Inc.
HOOKIPA Pharma Inc is a clinical-stage biopharmaceutical company developing a class of immunotherapeutics targeting infectious diseases and cancers based on its proprietary arenavirus platform that is designed to reprogram the body's immune system. Its oncology portfolio targets oncoviral cancer antigens and next-generation antigens and includes two primary programs in development: eseba-vec (formerly HB-200) and HB-700. Eseba-vec is in clinical development for the treatment of Human Papillomavirus 16-positive (HPV16+) head and neck cancers. It also develops infectious disease therapies in partnership with other companies. Its Hepatitis B (HBV) program, HB-400, and Human Immunodeficiency Virus (HIV) program, HB-500, are being developed in partnership with Gilead.
About CNFR Conifer Holdings Inc.
Conifer Holdings Inc is an insurance holding company. The company markets and services the product offerings of the company through specialty personal insurance business lines. The company offers insurance products in Texas, Illinois, and Indiana for homeowners lines and Nevada and Michigan for other lines. The revenues of the company are derived from premiums earned from insurance operations.